DeKarske D - Search Results

1

The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study.

Evidente VGH, DeKarske D, Coate B, Abler V. Evidente VGH, et al. Among authors: dekarske d. Ther Adv Neurol Disord. 2024 Mar 11;17:17562864241228350. doi: 10.1177/17562864241228350. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38476466 Free PMC article.

2

Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE Studies.

Bugarski-Kirola D, Abbs B, Odetalla R, Liu IY, Darwish M, DeKarske D. Bugarski-Kirola D, et al. Among authors: dekarske d. Patient Prefer Adherence. 2024 Jan 19;18:207-216. doi: 10.2147/PPA.S436041. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38264323 Free PMC article.

3

Population Pharmacokinetic Modeling and Stochastic Simulations to Support Pediatric Dose Selection of Pimavanserin.

Darwish M, Bugarski-Kirola D, Jaworowicz D, Owen J, Al Qaraghuli F, Barry A, DeKarske D. Darwish M, et al. Among authors: dekarske d. J Clin Pharmacol. 2023 Dec;63(12):1408-1416. doi: 10.1002/jcph.2315. Epub 2023 Aug 17. J Clin Pharmacol. 2023. PMID: 37471636

4

Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder.

Darwish M, Dirks B, Passarell J, Jaworowicz D, Bihorel S, Howell B, Owen J, DeKarske D, Stankovic S. Darwish M, et al. Among authors: dekarske d. Clin Pharmacol Drug Dev. 2023 May;12(5):463-474. doi: 10.1002/cpdd.1232. Epub 2023 Mar 7. Clin Pharmacol Drug Dev. 2023. PMID: 36880278

5

Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia: Results From the Phase 2 ADVANCE Study.

Darwish M, Bugarski-Kirola D, Passarell J, Owen J, Jaworowicz D, DeKarske D, Stankovic S. Darwish M, et al. Among authors: dekarske d. J Clin Psychopharmacol. 2022 Nov-Dec 01;42(6):544-551. doi: 10.1097/JCP.0000000000001611. Epub 2022 Oct 3. J Clin Psychopharmacol. 2022. PMID: 36190440 Free PMC article. Clinical Trial.

6

A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects.

Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. Darwish M, et al. Among authors: dekarske d. Clin Drug Investig. 2022 Jun;42(6):513-524. doi: 10.1007/s40261-022-01156-4. Epub 2022 May 27. Clin Drug Investig. 2022. PMID: 35622206 Free PMC article. Clinical Trial.

7

Palatability and Swallowability of Pimavanserin When Mixed with Selected Food Vehicles: An Exploratory Open-Label Crossover Study.

Forman M, Kouassi A, Brandt T, Barsky L, Zamora C, Dekarske D. Forman M, et al. Among authors: dekarske d. Geriatrics (Basel). 2021 Jun 15;6(2):61. doi: 10.3390/geriatrics6020061. Geriatrics (Basel). 2021. PMID: 34203662 Free PMC article.

8

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.

DeKarske D, Alva G, Aldred JL, Coate B, Cantillon M, Jacobi L, Nunez R, Norton JC, Abler V. DeKarske D, et al. J Parkinsons Dis. 2020;10(4):1751-1761. doi: 10.3233/JPD-202058. J Parkinsons Dis. 2020. PMID: 32804101 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters